Divided into three groups, a total of 525 children will be included in these clinical trials of Covaxin.
The All India Institute of Medical Sciences (AIIMS) Delhi is set to begin screening of children for the clinical trials of Covaxin, the indigenous Covid-19 vaccine developed by Bharat Biotech and ICMR.
AIIMS Delhi will begin the clinical trials of Covaxin on children aged 2-18 after AIIMS Patna, which started the trials recently on children aged between 12 and 18 years.
AIIMS Delhi, after getting permission from the Drugs Controller General of India (DCGI), is now starting the screening of children ahead of starting the clinical trials. The drug regulators approval was followed by a recommendation by the Subject Expert Committee (SEC) on May 12.
Divided into three groups, a total of 525 children will be included in these clinical trials of Covaxin.
The first group will have 175 children aged between 12 and 18 years while the second group will have 175 children aged between 6 and 12 years. Group 3 will have another 175 children aged between 2 and 6 years.
All 525 volunteers will receive two jabs of the vaccine through the intramuscular route. The second dose of Covaxin will be administered after 28 days.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
